{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:35:55Z","timestamp":1768314955294,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ypmed.2021.106641","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T11:54:17Z","timestamp":1621943657000},"page":"106641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts"],"prefix":"10.1016","volume":"150","author":[{"given":"M.","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jembere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kupets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"42","key":"10.1016\/j.ypmed.2021.106641_bb0005","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"},{"issue":"10197","key":"10.1016\/j.ypmed.2021.106641_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.ypmed.2021.106641_bb0015","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1016\/j.vaccine.2016.08.020","article-title":"Early impact of Ontario\u2019s human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment","volume":"34","author":"Guerra","year":"2016","journal-title":"Vaccine."},{"issue":"10108","key":"10.1016\/j.ypmed.2021.106641_bb0020","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomized, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.ypmed.2021.106641_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"14","key":"10.1016\/j.ypmed.2021.106641_bb0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"RR-2","key":"10.1016\/j.ypmed.2021.106641_bb0035","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.ypmed.2021.106641_bb0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"5","key":"10.1016\/j.ypmed.2021.106641_bb0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2021.106641_bb0050","author":"Prevention, C.f.D.C.a"},{"key":"10.1016\/j.ypmed.2021.106641_bb0060","author":"Public Health Ontario"},{"key":"10.1016\/j.ypmed.2021.106641_bb0055","author":"Public Health Ontario"},{"key":"10.1016\/j.ypmed.2021.106641_bb0065","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/ijc.30392","article-title":"Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries","volume":"139","author":"Simms","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.ypmed.2021.106641_bb0070","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1542\/peds.2014-2961","article-title":"The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts","volume":"135","author":"Smith","year":"2015","journal-title":"Pediatrics."},{"issue":"5","key":"10.1016\/j.ypmed.2021.106641_bb0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.vaccine.2012.11.090","article-title":"Coverage from Ontario, Canada\u2019s school-based HPV vaccine program: the first three years","volume":"31","author":"Wilson","year":"2013","journal-title":"Vaccine"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521002255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743521002255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:11:21Z","timestamp":1758795081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743521002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":15,"alternative-id":["S0091743521002255"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106641","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2021.106641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106641"}}